Lilly: Foundayo 17.2 mg outperforms oral semaglutide 25 mg on weight and A1C in indirect study

Eli Lilly said an indirect comparison presented at the European Association for the Study of Diabetes meeting in Milan found Foundayo 17.2 mg beat oral semaglutide 25 mg on weight and blood-sugar control in type 2 diabetes; oral semaglutide 25 mg is unapproved in the US.